Mezagitamab

Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1][2][3].

Product Specifications

CAS Number

[2227490-52-8]

Product Name Alternative

TAK-079

UNSPSC

12352203

Target

Apoptosis; CD38

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mezagitamab.html

Purity

99.79

Solubility

10 mM in DMSO

Smiles

[Mezagitamab]

Molecular Weight

(143.7 kDa)

References & Citations

[1]Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM) [J]. Blood, 2020, 136: 9.|[2]Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. |[3]Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196 (6) :1311-1328. |[4]Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6 (3) :e00402.|[5]Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370 (2) :182-196.